XORTX Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO XORTX Therapeutics is Allen Davidoff, benoemd in Jan2018, heeft een ambtstermijn van 6.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 321.96K, bestaande uit 79.2% salaris en 20.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.37% van de aandelen van het bedrijf, ter waarde $ 94.75K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.9 jaar en 4.1 jaar.

Belangrijke informatie

Allen Davidoff

Algemeen directeur

US$322.0k

Totale compensatie

Percentage CEO-salaris	79.2%
Dienstverband CEO	6.8yrs
Eigendom CEO	2.4%
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Allen Davidoff's beloning veranderd ten opzichte van XORTX Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$737k
Jun 30 2024	n/a	n/a	-US$1m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$322k	US$255k	-US$2m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	US$321k	US$273k	-US$8m
Sep 30 2022	n/a	n/a	US$1m
Jun 30 2022	n/a	n/a	-US$3m
Mar 31 2022	n/a	n/a	-US$2m
Jan 01 2022	n/a	n/a	-US$2m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$204k	US$154k	-US$1m
Sep 30 2020	n/a	n/a	-US$767k
Jun 30 2020	n/a	n/a	-US$536k
Mar 31 2020	n/a	n/a	-US$362k
Dec 31 2019	US$161k	US$148k	-US$485k
Sep 30 2019	n/a	n/a	-US$444k
Jun 30 2019	n/a	n/a	-US$582k
Mar 31 2019	n/a	n/a	-US$660k
Dec 31 2018	US$194k	US$141k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 321.96K ) Allen } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Allen is gestegen terwijl het bedrijf verliesgevend is.

CEO

Allen Davidoff (64 yo)

6.8yrs

Tenure

US$321,959

Compensatie

Dr. Allen Warren Davidoff, Ph.D. is Founder of XORTX Therapeutics Inc. (formerly known as XORTX Pharma Corp.) and has been its Chief Executive Officer and President since January 9, 2018. Dr. Davidoff serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Allen Davidoff	Founder	6.8yrs	US$321.96k	2.37% $ 94.8k
James Fairbairn	Chief Financial Officer	1.4yrs	US$57.51k	0.22% $ 8.6k
Stephen Haworth	Chief Medical Officer	3.3yrs	US$173.37k	0% $ 0
Stacy Evans	Chief Business Officer	2yrs	US$211.33k	geen gegevens
Nick Rigopoulos	Director of Communications	no data	geen gegevens	geen gegevens
David Sans	Director of Corporate Development	4.3yrs	geen gegevens	geen gegevens
David MacDonald	Consultant of Clinical Operations	2.5yrs	geen gegevens	geen gegevens
Charlotte May	Corporate Secretary	no data	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van XRTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Allen Davidoff	Founder	6.8yrs	US$321.96k	2.37% $ 94.8k
Paul Van Damme	Independent Director	6.8yrs	US$8.20k	0.22% $ 8.8k
Anthony Giovinazzo	Independent Chair of the Board	2.4yrs	US$101.11k	0.30% $ 11.9k
Richard Johnson	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
William Farley	Independent Director	3.5yrs	US$7.87k	0% $ 0
Raymond Pratt	Independent Director	2.9yrs	US$7.37k	0% $ 0
Henk E. D. ter Keurs	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Federico Maese	Member of Clinical Advisory Board	6.1yrs	geen gegevens	geen gegevens
Patrick Treanor	Independent Director	less than a year	geen gegevens	0% $ 0
Petter Bjornstad	Member of Clinical Advisory Board	6.1yrs	geen gegevens	geen gegevens
Anjay Rastogi	Member of the Clinical Advisory Board	4.7yrs	geen gegevens	geen gegevens
Charles Edelstein	Member of the Advisory Board	3.3yrs	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

68.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van XRTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

XORTX Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors

XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Board Changes

XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux

Recent updates

New major risk - Shareholder dilution

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.499994 million.

XORTX Therapeutics Inc. Initiates Precision Medicine Program

New major risk - Share price stability

XORTX Therapeutics Inc. announced delayed 20-F filing

XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors

XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board

XORTX Therapeutics Inc. announced a financing transaction

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Board Changes

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million.

New major risk - Revenue and earnings growth

XORTX Therapeutics Inc. Announces Presentation of New Research Findings At the American Society of Nephrology Meeting

XORTX Therapeutics to Consider A Consolidation of the Company’s Issued and Outstanding Shares in Order for the Company to Regain Compliance with the Continued Listing Requirements for the Nasdaq Capital Market

XORTX Therapeutics Provides Nasdaq Compliance Update

New major risk - Share price stability

Xortx Therapeutics Inc. Submits Orphan Drug Designation Application to the European Medicines Agency to Treat Progressive Kidney Disease

New major risk - Market cap size

XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux

XORTX Therapeutics Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics Inc. Announces FDA Confirms Eligibility of XORLO™ for Accelerated Approval

XORTX Therapeutics Inc. Announces Goals for 2023

Xortx Therapeutics Inc. Announces Submission of Orphan Drug Designation Request for Xrx-008 Program to Treat Autosomal Dominant Kidney Disease

XORTX Therapeutics Inc. Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

XORTX Therapeutics Inc Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

XORTX Therapeutics Inc. Announces Completion of Dosing in XRX-OXY-101 Clinical Study

XORTX Therapeutics Inc. Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

XORTX Therapeutics Appoints Stacy Evans as Chief Business Officer

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives Further No Objection Letter from Health Canada

XORTX Therapeutics Inc. has completed a Composite Units Offering in the amount of $4.99964 million.

XORTX Therapeutics Inc. Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

XORTX completes positive pre-phase 3 meeting with the FDA

XORTX Therapeutics Inc. Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Submission to European Medicines Agency

XORTX Therapeutics Inc. Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

XORTX jumps over 100% after early encouraging data for rare disease therapy

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

XORTX Therapeutics Inc. Appoints Anthony Giovinazzo to the Board of Directors and as Chair of the Board

XORTX Therapeutics Inc., Annual General Meeting, Jul 20, 2022

XORTX Therapeutics Inc. Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

XORTX Therapeutics Inc. Initiates Dosing of Human Subjects in the Xrx-Oxy-101 Clinical Trial

XORTX Therapeutics Inc. announced delayed 20-F filing

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives No Objection Letter from Health Canada

XORTX Therapeutics Inc. Announces Grant of US Patent

Xortx Therapeutics Inc. Announces Filing of an Investigational New Drug Application with the Unites States Food and Drug Administration

XORTX Therapeutics Inc. Provides Corporate Update for 2022

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

XORTX Therapeutics Inc. Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

High number of new and inexperienced directors

XORTX Therapeutics Inc., Annual General Meeting, Apr 29, 2021

XORTX Therapeutics Inc. Announces the Filing of A New Provisional Patent Application Entitled "Compositions and Methods for Enhancing Anti-Viral Therapies"

XORTX Therapeutics Inc. announced that it has received CAD 6.121572 million in funding

XORTX Therapeutics Inc. announced that it expects to receive CAD 3 million in funding

XORTX Announces Grant of European Patent

XORTX Therapeutics Inc. Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

XORTX Therapeutics Inc. Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd